Restricted accessResearch articleFirst published online 2025-5
The Effect of Beta-Blocker Post-Myocardial Infarction With Ejection Fraction >40% Pooled Analysis From Seven Arabian Gulf Acute Coronary Syndrome Registries
The use of beta-blockers (BB) in reduced left ventricular ejection fraction (LVEF) post-myocardial infarction (MI) is associated with reduced 1-year mortality, while their role in patients with mid-range and preserved LVEF post-MI remains controversial. We studied 31,620 patients who presented with acute coronary syndrome (ACS) enrolled in seven Arabian Gulf registries between 2005 and 2017. Patients with LVEF ≤40% were excluded. The remaining cohort was divided into two groups: BB group (n = 15,541) and non-BB group (n = 2,798), based on discharge medications. Patients in the non-BB group were relatively younger (55.3 vs. 57.4, P = .004) but higher risk at presentation; with higher Global Registry of Acute Coronary Events (GRACE) score (119.2 vs 109.2, P < .001), higher percentage of cardiogenic shock (3.5 vs 1.4%, P < .001), despite lower prevalence of comorbidities, such as hypertension and hyperlipidemia. BB use was associated with lower 1-year mortality in a multivariate logistic regression analysis, adjusting for major confounders [adjusted odds ratio (OR): 0.71 (95% CI 0.51–0.99)]. This remained the case in a sensitivity analysis using propensity score matching [adjusted OR: 0.34 (95% CI 0.16–0.73)]. In this study, using Arabian Gulf countries registries, the use of BB after ACS with LVEF >40% was independently associated with lower 1-year mortality.
The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet. 1999;353(9146):9-13.
2.
PackerMBristowMRCohnJNColucciWSFowlerMBGilbertEM, et al.The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334(21):1349-1355.
3.
Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in-congestive heart failure (MERIT-HF). Lancet. 1999;353(9169):2001-2007.
4.
RydénLAriniegoRArnmanKHerlitzJHjalmarsonAHolmbergS, et al.A double-blind trial of metoprolol in acute myocardial infarction. Effects on ventricular tachyarrhythmias. N Engl J Med. 1983;308(11):614-618.
5.
COMMIT (CIOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Early intravenous then oral metoprolol in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366(9497):1622-1632.
6.
AmsterdamEAWengerNKBrindisRGCaseyDEGaniatsTGHolmesDR, et al.2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American heart association task force on practice guidelines. J Am Coll Cardiol. 2014;64(24):e139-e228.
7.
FreemantleNClelandJYoungPMasonJHarrisonJ. Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ. 1999;318:8.
8.
de PeuterORLussanaFPetersRJGBüllerHRKamphuisenPW. A systematic review of selective and non-selective beta blockers for prevention of vascular events in patients with acute coronary syndrome or heart failure. Neth J Med. 2009;67(9):284-294.
9.
LawtonJSTamis-HollandJEBangaloreSBatesERBeckieTMBischoffJM, et al2021 ACC/AHA/SCAI guideline for coronary artery revascularization: executive summary: a report of the American College of Cardiology/American heart association joint committee on clinical practice guidelines. Circulation. 2022;145(3):e4-e17.
10.
HoltABlanchePZareiniBRajanDEl-SheikhMSchjerningAM, et al.Effect of long-term beta-blocker treatment following myocardial infarction among stable, optimally treated patients without heart failure in the reperfusion era: a Danish, nationwide cohort study. Eur Heart J. 2021;42(9):907-914.
11.
BangaloreSMakaniHRadfordMThakurKTokluBKatzSD, et al.Clinical outcomes with β-blockers for myocardial infarction: a meta-analysis of randomized trials. Am J Med. 2014;127(10):939-953.
12.
Dahl AarvikMSandvenIDondoTBGaleCPRuddoxVMunkhaugenJ, et al.Effect of oral β-blocker treatment on mortality in contemporary post-myocardial infarction patients: a systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother. 2019;5(1):12-20.
13.
NeumannAMauraGWeillAAllaFDanchinN. Clinical events after discontinuation of β-blockers in patients without heart failure optimally treated after acute myocardial infarction: a cohort study on the French healthcare databases. Circ Cardiovasc Qual Outcomes.2018;11(4):e004356.
14.
KimJKangDParkHKangMParkTKLeeJM, et al.Long-term β-blocker therapy and clinical outcomes after acute myocardial infarction in patients without heart failure: nationwide cohort study. Eur Heart J. 2020;41(37):3521-3529.
15.
ChooEHChangKAhnYJeonDSLeeJMKimDB, et al.Benefit of β-blocker treatment for patients with acute myocardial infarction and preserved systolic function after percutaneous coronary intervention. Heart. 2014; 100(6):492-499.
16.
Raposeiras-RoubínSAbu-AssiERedondo-DiéguezAGonzález-FerreiroRLópez-LópezABouzas-CruzN, et al.Prognostic benefit of beta-blockers after acute coronary syndrome with preserved systolic function. Still relevant today?Rev Esp Cardiol. 2015;68(7):585-591.
17.
IshakDAktaaSLindhagenLAlfredssonJDondoTBHeldC, et al.Association of beta-blockers beyond 1 year after myocardial infarction and cardiovascular outcomes. Heart. 2023;109(15):1159-1165.
18.
KonishiHMiyauchiKKasaiTTsuboiSOgitaMNaitoR, et al.Long-term effect of β-blocker in ST-segment elevation myocardial infarction in patients with preserved left ventricular systolic function: a propensity analysis. Heart Ves. 2016;31(4):441-448.
19.
PuymiratERiantEAissaouiNSoriaADucrocqGCosteP, et al.β blockers and mortality after myocardial infarction in patients without heart failure: multicentre prospective cohort study. BMJ. 2016;354:i4801.
20.
ShehabAAl-DabbaghBAlHabibKFAlsheikh-AliAAAlmahmeedWSulaimanK, et al.Gender disparities in the presentation, management and outcomes of acute coronary syndrome patients: data from the 2nd Gulf registry of acute coronary events (Gulf RACE-2). PLoS One. 2013;8(2):e55508.
21.
El-MenyarAZubaidMSulaimanKAlMahmeedWSinghRAlsheikh-AliAA, et al.Atypical presentation of acute coronary syndrome: a significant independent predictor of in-hospital mortality. J Cardiol. 2011;57(2):165-171.
22.
AlhabibKFHersiAAlfalehHAlnemerKAlsaifSTarabenA, et al.Baseline characteristics, management practices, and in-hospital outcomes of patients with acute coronary syndromes: results of the Saudi project for assessment of coronary events (SPACE) registry. J Saudi Heart Assoc. 2011;23(4):233-239.
23.
ZubaidMRashedWAlsheikh-AliAAGaradahTAlrawahiNRidhaM, et al.Disparity in ST-segment elevation myocardial infarction practices and outcomes in arabian Gulf countries (Gulf COAST registry). Heart Views. 2017;18(2):41-46.
24.
AlHabibKFSulaimanKAl SuwaidiJAlmahmeedWAlsheikh-AliAAAminH, et al.Patient and system-related delays of emergency medical services use in acute ST-elevation myocardial infarction: results from the third Gulf registry of acute coronary events (Gulf RACE-3ps). PLoS One. 2016;11(1):e0147385.
25.
AlhabibKFKinsaraAJAlghamdiSAl-MurayehMHusseinGAAlSaifS, et al.The first survey of the Saudi acute myocardial infarction registry program: main results and long-term outcomes (STARS-1 program). PLoS One. 2019;14(5):e0216551.
26.
ZubaidMKhraishahHAlahmadBRashedWRidhaMAleneziF, et al.Efficacy and safety of pharmacoinvasive strategy compared to primary percutaneous coronary intervention in the management of ST-segment elevation myocardial infarction: a prospective country-wide registry. Ann Glob Health. 2020;86(1):13.
27.
ZubaidMRashedWAAlmahmeedWAl-LawatiJSulaimanKAl-MotarrebA, et al.Management and outcomes of middle eastern patients admitted with acute coronary syndromes in the Gulf registry of acute coronary events (Gulf RACE). Acta Cardiol. 2009;64(4):439-446.
28.
AlHabibKFSulaimanKAl-MotarrebAAlmahmeedWAsaadNAminH, et al.Baseline characteristics, management practices, and long-term outcomes of middle eastern patients in the second Gulf registry of acute coronary events (Gulf RACE-2). Ann Saudi Med. 2012;32(1):9-18.
29.
Al-ZakwaniIAl SiyabiEAlrawahiNAl-MullaAAlnaeemiAShehabA, et al.Association between peripheral artery disease and major adverse cardiovascular events in patients with acute coronary syndrome: findings from the Gulf COAST registry. Med Princ Pract. 2019;28(5):410-417.
30.
ShehabABhagavathulaASAlhabibKFUllahASuwaidiJAAlmahmeedW, et al.Age‐related sex differences in clinical presentation, management, and outcomes in ST‐segment–elevation myocardial infarction: pooled analysis of 15 532 patients from 7 arabian Gulf registries. J Am Heart Assoc. 2020;9(4):e013880.
31.
KotrlikJWilliamsHJaborK. Reporting and interpreting effect size in quantitative agricultural education Research. J Agric Educ. 2011;52(1):132-142.
32.
MamdaniMSykoraKLiPNormandSLTStreinerDLAustinPC, et alReader’s guide to critical appraisal of cohort studies: 2. Assessing potential for confounding. BMJ. 2005;330(7497):960-962.
33.
ChenRZLiuCZhouPLiJNZhouJYWangY, et alPrognostic impacts of β-blockers in acute coronary syndrome patients without heart failure treated by percutaneous coronary intervention. Pharmacol Res. 2021;169:105614.
34.
Abi KhalilCAlHabibKFSinghRAsaadNAlfalehHAlsheikh-AliAA, et al.β-Blocker therapy prior to admission for acute coronary syndrome in Patients without heart failure or left ventricular dysfunction improves in-hospital and 12-month outcome: results from the GULF-RACE 2 (Gulf registry of acute coronary events-2). J Am Heart Assoc. 2017;6(12):e007631.
35.
Montenegro SáFCarvalhoRRuivoCSantosLGAntunesASoaresF, et al.Beta-blockers for post-acute coronary syndrome mid-range ejection fraction: a nationwide retrospective study. Eur Heart J Acute Cardiovasc Care. 2019;8(7):599-605.
36.
Abi KhalilCZubaidMMekhaimarMAsaadNMahfoudZAl SuwaidiJ. Beta-blockers and short-term cardiovascular outcomes in patients hospitalized for acute coronary syndrome and a left ventricular ejection fraction ≥40. Sci Rep. 2020;10(1): 3520.
37.
HuangBTHuangFYZuoZLLiaoYBHengYWangPJ, et alMeta-analysis of relation between oral β-blocker therapy and outcomes in patients with acute myocardial infarction who underwent percutaneous coronary intervention. Am J Cardiol. 2015;115(11):1529-1538.
38.
DondoTBHallMWestRMJernbergTLindahlBBuenoH, et al.β-Blockers and mortality after acute myocardial infarction in patients without heart failure or ventricular dysfunction. J Am Coll Cardiol. 2017;69(22):2710-2720.
39.
El NasasraABeigelRKlempfnerRAlnsasraHMatetzkySIakobishviliZ, et al.Comparison of outcomes with or without beta-blocker therapy after acute myocardial infarction in patients without heart failure or left ventricular systolic dysfunction (from the acute coronary syndromes Israeli survey [ACSIS]). Am J Cardiol. 2021;143:1-6.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
